早期穿刺移植物对终末期肾病患者医疗质量与成本的影响
本研究对397例终末期肾病患者的透析通路创建进行回顾性财务分析,比较动静脉内瘘与早期穿刺移植物在一年内的总医疗成本。结果显示早期穿刺移植物组平均成本为5894美元,显著低于动静脉内瘘组的17523美元(P<0.01),主要归因于减少中心静脉导管相关并发症和二次干预。
要点
- 早期穿刺移植物一年平均成本5894美元,显著低于动静脉内瘘的17523美元(P<0.01)。
- 减少中心静脉导管相关并发症和二次干预为每例患者节省11630美元,主要来自耗材成本。
- 中心静脉导管使用减少使脓毒症相关成本再降1083美元,并因住院时间和ICU使用减少带来额外年度节省。
核心结论
- 对于需要紧急起始透析的终末期肾病患者,使用早期穿刺移植物比使用动静脉内瘘加中心静脉导管具有显著的成本节约。
- 成本节约主要归因于中心静脉导管相关并发症减少和二次干预减少。
研究设计与样本
- 回顾性财务分析,纳入2014年7月至2018年10月期间连续397例接受透析通路创建的患者。
- 评估指标包括通路方式、并发症、二次干预、住院结局和医疗成本,在索引手术时、30天、90天、180天、270天和一年时测量。
主要发现
- 131例患者接受动静脉内瘘,266例接受早期穿刺移植物。
- 一年平均医疗成本:动静脉内瘘组17523美元,早期穿刺移植物组5894美元(P<0.01)。
- 早期穿刺移植物相关更少的中心静脉导管并发症和二次干预,每例患者节省11630美元,主要来自供应成本。
- 早期穿刺移植物组中心静脉导管使用更少,使一年脓毒症减少相关成本再降低1083美元。
临床怎么用
- 在终末期肾病需紧急起始透析的患者中,可考虑优先使用早期穿刺移植物以降低中心静脉导管使用及相关并发症。
- 早期穿刺移植物的应用可能通过减少二次干预和住院资源使用而降低整体医疗成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The annual cost of care associated with end-stage renal disease (ESRD) per patient on hemodialysis is approaching $100,000, with nearly $42 billion in national spend per year. Early cannulation arteriovenous grafts (ECAVGs) help decrease the use of central venous catheters (CVCs), thus potentially decreasing the cost of care. However, a formal financial analysis that also includes the cost of CVC-related complications and secondary interventions has not been completed. The purpose of this project is to evaluate the overall financial costs associated with ECAVGs on patients with ESRD during a one-year period. METHODS: Access modality, complications, secondary interventions, hospital outcomes, and cost of care were determined for 397 sequential patients who underwent access creation between July 2014 and October 2018. A detailed financial analysis was completed, including an evaluation of implant, supplies, medications, laboratories, labor, and other direct costs. All variables were measured at the time of the index procedure, 30 days, 90 days, 180 days, 270 days, and one year. RESULTS: There were 131 patients who underwent arteriovenous fistula (AVF) and 266 who underwent ECAVG for dialysis access. The average cost of care was $17,523 for AVF and $5,894 for ECAVG at one year (P < 0.01). Fewer CVC-related complications and secondary interventions associated with ECAVGs saved $11,630 per patient with ESRD, primarily in the form of supply costs. Fewer CVCs in the patients receiving ECAVGs led to an additional $1,083 decrease in cost associated with sepsis reduction at one year. A subsequent decrease in length of stay and ICU utilization led to an additional $2.0 million decrease in annual cost of care for patients with ESRD. CONCLUSIONS: The use of ECAVGs has significant cost savings over using an AVF and CVC for urgent-start dialysis in patients with ESRD. This cost savings is secondary to decreased CVC-related complications and fewer secondary interventions. Significant national savings are possible with appropriate use of ECAVGs in patients with ESRD.
引用
- Desai SS. Impact of Early Cannulation Grafts on Quality and Cost of Care for Patients With End-Stage Renal Disease. Ann Vasc Surg. 2019. PMID: 31200049. doi:10.1016/j.avsg.2019.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。